Ergonovine Alternatives Compared
| Ergonovine | Medroxyprogesterone | Norethindrone |
|
|---|
| Ergonovine | Medroxyprogesterone | Norethindrone |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Abnormal Uterine Bleeding, Postpartum Bleeding. Ergonovine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Abnormal Uterine Bleeding, Endometrial Hyperplasia - Prophylaxis, Amenorrhea, Birth Control, Endometrial Cancer, Endometriosis, Gender Affirming Hormone Therapy, Gender Dysphoria... View more |
Prescription only
Prescribed for Abnormal Uterine Bleeding, Endometriosis, Amenorrhea, Gender Affirming Hormone Therapy, Birth Control. Norethindrone may also be used for purposes not listed in this medication guide. |
||||||||
| More about Ergonovine | More about Medroxyprogesterone | More about Norethindrone | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Medroxyprogesterone has an average rating of 4.5 out of 10 from a total of 2474 ratings on Drugs.com. 30% of reviewers reported a positive effect, while 51% reported a negative effect. |
Norethindrone has an average rating of 4.9 out of 10 from a total of 1574 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 45% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Ergonovine side effects |
View all Medroxyprogesterone side effects |
View all Norethindrone side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
Lower cost generic |
Lower cost generic |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Medroxyprogesterone prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
|
||||||||
| Brand Names | ||||||||||
|
N/A |
Depo Provera, depo-subQ provera 104, Provera | Affodel, Camila, Deblitane, Emzahh, Errin, Gallifrey, Heather, Incassia, Jencycla, Lyleq, Lyza, Meleya, Nor-QD, Norlyda, Norlyroc, Orquidea, Sharobel, Tulana View more | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
N/A |
401 hours |
10 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category N
Not classified
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 271 drugs are known to interact with Ergonovine:
|
A total of 256 drugs are known to interact with Medroxyprogesterone:
|
A total of 267 drugs are known to interact with Norethindrone:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
June 18, 1959 |
April 21, 1982 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.